← The Wire
REGNNasdaq
REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · NY · CIK 872589
Regeneron Pharmaceuticals discovers, develops, and commercializes medicines for serious diseases
⚡ Elevated coverage
$64.18B
Market cap
$631.81
Last close
-0.2%
1D
+3.1%
5D
734K
Volume
Price · last 39 sessions-10.9%
May 4L $600.66 · H $723.41Jun 29
165
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
10-Q10-QApr 29, 202610-Q10-QOct 28, 202510-Q10-QAug 1, 202510-Q10-QApr 29, 202510-Q10-QOct 31, 202410-Q10-QAug 1, 202410-Q10-QMay 2, 202410-Q10-QNov 2, 202310-Q10-QAug 3, 202310-Q10-QMay 4, 202310-Q10-QNov 3, 202210-Q10-QAug 3, 202210-Q10-QMay 4, 202210-Q10-QNov 4, 202110-Q10-QAug 5, 202110-Q10-QMay 6, 202110-Q10-QNov 5, 202010-Q10-QAug 5, 202010-QFORM 10-QMay 5, 202010-QFORM 10-QNov 5, 201910-QFORM 10-QAug 6, 201910-QFORM 10-QMay 7, 201910-QFORM 10-QNov 6, 201810-QFORM 10-QAug 2, 201810-QFORM 10-QMay 3, 201810-QFORM 10-QNov 8, 201710-QFORM 10-QAug 3, 201710-QFORM 10-QMay 4, 2017
Insider Activity
In the 90 days to Mar 2, 2026: 4 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $789.28 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $788.96 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 11 | $785.48 | $9K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 10 | $783.62 | $8K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 9 | $784.48 | $7K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $786.61 | $6K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $777.46 | $5K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 5 | $779.69 | $4K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 3 | $780.69 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $787.34 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $782.62 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $781.21 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $778.30 | $2K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 331 | $780.45 | $258K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 298 | $782.10 | $233K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 220 | $783.29 | $172K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 209 | $781.28 | $163K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 208 | $779.55 | $162K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 160 | $784.45 | $126K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 56 | $785.61 | $44K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 5 reputable articles · skews – neutral.
MarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day12d agoMarketWatchRegeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market18d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors21d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains24d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains25d agoMarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance